This is the text extract for 2011-06 Schedule Dispatch, browse documents here.

18 May 2011 June 2011 Pharmaceutical Schedule Dispatch This document is provided to pharmacists as an early notification of the changes to be announced in the June 2011 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details. New listings  Cilazapril (Zapril) tab 2.5 mg, 90 pack (p’code 2379082) and 5 mg, 90 pack (p’code 2379090)  Triclosan (Pharmacy Health) soln 1%, 500 ml OP – maximum of 500 ml per prescription – subsidy by endorsement (p’code 2366843)  Ornidazole (Arrow-Ornidazole) tab 500 mg (p’code 2385325)  Morphine sulphate (Arrow-Morphine LA) – only on a controlled drug form – no patient co-payment payable o tab long acting 10 mg (p’code 2383934) o tab long acting 30 mg (p’code 2383942) o tab long acting 60 mg (p’code 2383918) o tab long acting 100 mg (p’code 2383926)  Olanzapine (Dr Reddy’s Olanzapine) – no Special Authority required o tab 2.5 mg (p’code 2380781) o tab 5 mg (p’code 2380803) o tab 10 mg (p’code 2380811) o orodispersible tab 5 mg (p’code 2380838) o orodispersible tab 10 mg (p’code 2380846)  Olanzapine (Olanzine and Olanzine-D) – no Special Authority required o tab 2.5 mg (p’code 2376385) o tab 5 mg, (p’code 2376393) o tab 10 mg (p’code 2376407) o orodispersible tab 5 mg (p’code 2376369) o orodispersible tab 10 mg (p’code 2376377)  Methotrexate (DBL Methotrexate) inj 25 mg per ml, 40 ml – PCT – Retail pharmacySpecialist – Section 29 (p’code 2384922)  Bortezomib inj 1 mg (Velcade) (p’code 2383055) and inj 1 mg for ECP, 1 mg (Baxter) (p’code 2383667) – PCT only – Specialist – Special Authority  Doxorubicin (DBL Doxorubicin) inj 50 mg – PCT only – Specialist – Section 29 (p’code 780022)  Paclitaxel (Anzatax) inj 150 mg (p’code 2371826) and 300 mg (p’code 2271818) – PCT only – Specialist Changes to restrictions  Azithromycin (Arrow-Azithromycin) tab 500 mg – amended Special Authority criteria  Clarithromycin (Klacid and Klamycin) tab 250 mg and grans for oral liq 125 mg per 5 ml – amended Special Authority criteria  Fluconazole (Pacific) cap 150 mg – removal of Retail pharmacy-Specialist, addition of subsidy by endorsement, and only 1 cap subsidised per prescription  Pegylated interferon alpha-2A (Pegasys and Pegasys RBV Combination Pack) inj prefilled syringe with or without ribavarin – amended Special Authority criteria  Sumatriptan (Arrow-Sumatriptan and Imigran) inj 12 mg per ml, 0.5 ml – removal of Retail pharmacy-Specialist

A424244 - qA19571



Bortezomib inj 1 mg and 3.5 mg (Velcade), and inj 1 mg for ECP (Baxter) – amended Special Authority criteria

Decreased subsidy Chemical Cefaclor monhydrate Sumatriptan Naltrexone hydrochloride Tamoxifen citrate Ipratropium bromide Presentation Cap 250 mg Inj 12 mg per ml, 0.5 ml Tab 500 mg Fully subsidised brands Partially subsidised brands Cefaclor Sandoz Arrow-Sumatriptan Ranbaxy–Cefaclor Imigran

Naltraccord ReVia Tab 20 mg Genox Aqueous nasal spray Univent 0.03%, 30 ml OP

Tamoxifen Sandoz Apo-Ipravent

Increased subsidy Chemical Sodium fluoride Presentation Tab 1.1 mg (0.5 mg elemental) Fully subsidised brands PSM

NB. For further details and magnitude of the above subsidy changes, please consult the online version of the Update to the Pharmaceutical Schedule at: www.pharmac.govt.nz/healthpros/Schedule.

Medicines Regulations changes – not yet in force Medsafe has advised us that the proposed changes to the Medicines Regulations described in the March edition of Medsafe’s Prescriber Update are not yet in force. This means that the maximum period of supply is still three months for prescription medicines except oral contraceptives which is six months. The Ministry of Health will inform healthcare professionals of the date the changes will come into force. Further information about the proposed changes to the Medicines Regulations is available from Medsafe at: http://www.medsafe.govt.nz/profs/PUArticles/ChangestoMedicinesRegulations.htm

A424244 - qA19571